On the public citation graph
Market Incentives and the Drug Development Pipeline: Evidence from Antibiotics
0 signed · 50 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.281.1.61openalex-extracted
Trends in Infectious Disease Mortality in the United States During the 20th Century
inferredcites →https://doi.org/10.1002/cpt.1627openalex-extracted
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases
inferredcites →https://doi.org/10.1002/phar.1868openalex-extracted
Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications
inferredcites →https://doi.org/10.1016/j.jeconom.2023.03.008openalex-extracted
What’s trending in difference-in-differences? A synthesis of the recent econometrics literature
inferredcites →https://doi.org/10.1016/j.jfineco.2022.01.004openalex-extracted
How much should we trust staggered difference-in-differences estimates?
inferredcites →https://doi.org/10.1016/j.jhealeco.2008.01.002openalex-extracted
Market incentives and pharmaceutical innovation
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-extracted
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1016/j.jpubeco.2012.10.003openalex-extracted
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
inferredcites →https://doi.org/10.1016/s0140-6736(21)02724-0openalex-extracted
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
inferredcites →https://doi.org/10.1016/s0167-6296(02)00126-1openalex-extracted
The price of innovation: new estimates of drug development costs
inferredcites →https://doi.org/10.1016/s0169-7218(10)02009-5openalex-extracted
Patent Statistics as an Innovation Indicator
inferredcites →https://doi.org/10.1038/clpt.2009.295openalex-extracted
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
inferredcites →https://doi.org/10.1038/d41573-019-00074-zopenalex-extracted
Trends in clinical success rates and therapeutic focus
inferredcites →https://doi.org/10.1038/d41586-020-02884-3openalex-extracted
Why big pharma has abandoned antibiotics
inferredcites →https://doi.org/10.1038/nbt.2786openalex-extracted
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nrd2201openalex-extracted
Drugs for bad bugs: confronting the challenges of antibacterial discovery
inferredcites →https://doi.org/10.1038/s41579-019-0293-3openalex-extracted
Antibiotic development — economic, regulatory and societal challenges
inferredcites →https://doi.org/10.1093/biostatistics/kxx069openalex-extracted
Estimation of clinical trial success rates and related parameters
inferredcites →https://doi.org/10.1093/cid/ciaa1527openalex-extracted
Diagnostic Tests Can Stem the Threat of Antimicrobial Resistance: Infectious Disease Professionals Can Help
inferredcites →https://doi.org/10.1093/cid/cir153openalex-extracted
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
inferredcites →https://doi.org/10.1093/ofid/ofaa001openalex-extracted
Incentivizing Antibiotic Development: Why Isn’t the Generating Antibiotic Incentives Now (GAIN) Act Working?
inferredcites →https://doi.org/10.1093/qje/qjs032openalex-extracted
Market Power Screens Willingness-to-Pay*
inferredcites →https://doi.org/10.1093/rfs/hhab024openalex-extracted
Missing Novelty in Drug Development
inferredcites →https://doi.org/10.1097/00132586-199910000-00014openalex-extracted
Trends in Infectious Disease Mortality in the United States During the 20th Century
inferredcites →https://doi.org/10.1111/1756-2171.12113openalex-extracted
Market size and pharmaceutical innovation
inferredcites →https://doi.org/10.1111/1756-2171.12422openalex-extracted
Does consumer demand pull scientifically novel drug innovation?
inferredcites →https://doi.org/10.1111/j.1574-695x.1999.tb01389.xopenalex-extracted
Respiratory viral infection predisposing for bacterial disease: a concise review
inferredcites →https://doi.org/10.1126/science.aaa2868openalex-extracted
A return to the pre-antimicrobial era?
inferredcites →https://doi.org/10.1126/science.aal0010openalex-extracted
The applied value of public investments in biomedical research
inferredcites →https://doi.org/10.1162/0033553041382166openalex-extracted
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
inferredcites →https://doi.org/10.1162/0033553041502144openalex-extracted
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
inferredcites →https://doi.org/10.1162/rest_a_00214openalex-extracted
Investments in Pharmaceuticals Before and After TRIPS
inferredcites →https://doi.org/10.1162/rest_a_00987openalex-extracted
Patents, Data Exclusivity, and the Development of New Drugs
inferredcites →https://doi.org/10.1215/00703370-9368970openalex-extracted
Technological Progress and Health Convergence: The Case of Penicillin in Postwar Italy
inferredcites →https://doi.org/10.1257/aer.20131176openalex-extracted
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
inferredcites →https://doi.org/10.1257/aeri.20210063openalex-extracted
Insurance Design and Pharmaceutical Innovation
inferredcites →https://doi.org/10.1257/app.2.2.118openalex-extracted
Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs
inferredcites →https://doi.org/10.1257/jep.33.3.163openalex-extracted
A Toolkit of Policies to Promote Innovation
inferredcites →https://doi.org/10.1257/pandp.20201014openalex-extracted
Preventing the Spread of Antibiotic Resistance
inferredcites →https://doi.org/10.1257/pandp.20201017openalex-extracted
Advance Market Commitments: Insights from Theory and Experience
inferredcites →https://doi.org/10.1377/hlthaff.2014.1003openalex-extracted
Repairing The Broken Market For Antibiotic Innovation
inferredcites →https://doi.org/10.1377/hlthaff.2017.1179openalex-extracted
Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period
inferredcites →https://doi.org/10.1377/hlthaff.2020.00284openalex-extracted
Contributions Of Public Health, Pharmaceuticals, And Other Medical Care To US Life Expectancy Changes, 1990-2015
inferredcites →https://doi.org/10.1377/hlthaff.2021.00688openalex-extracted
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines
inferredcites →https://doi.org/10.2307/4588443openalex-extracted
Mortality in the United States, 1900-1950
inferredcites →https://doi.org/10.3386/w27563openalex-extracted
Insurance Design and Pharmaceutical Innovation
inferredcites →https://doi.org/10.3389/fmicb.2017.01041openalex-extracted
Secondary Bacterial Infections Associated with Influenza Pandemics
inferredcites →https://doi.org/10.3982/ecta17635openalex-extracted
Are Medical Care Prices Still Declining? A Re‐Examination Based on Cost‐Effectiveness Studies
inferredcites →https://doi.org/10.7326/m16-0291openalex-extracted
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration–Approved Antibiotics, 2010–2015
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.